{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:16:44Z","timestamp":1788322604438,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background and aim<\/jats:title>\n            <jats:p>Data about the safety and efficacy of direct-acting antivirals (DAAs) in the treatment of hepatitis C virus (HCV) patients with concomitant rheumatoid arthritis (RA) are scarce. We assessed the impact and safety of DAAs treatment of hepatitis C on rheumatoid arthritis disease activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Prospectively, we enrolled 65 patients with RA and HCV. A clinico-laboratory evaluation was done at baseline, including liver assessment and RA disease activity score-28 (DAS28). At 12\u2009weeks of post-DAAs treatment, sustained virologic response (SVR12) and DAS28 were reevaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The SVR12 was achieved in 59 (90.8%) patients. RA control was achieved in 47 (79.9%) patients. The post SVR12 DAS28 score was significantly lower than the baseline (3.32\u2009\u00b1\u20090.93 vs. 4.37\u2009\u00b1\u20090.90; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). There was a significant decline in the mean values of serum anticyclic citrullinated peptide, rheumatoid factor, erythrocyte sedimentation rate and C-reactive protein after achieving an SVR12 (30.47\u2009\u00b1\u200912.37 vs. 57.61\u2009\u00b1\u200915.91\u2009U\/ml; 29.78\u2009\u00b1\u200919.58 vs. 55.14\u2009\u00b1\u200916.89 IU\/ml; 17.13\u2009\u00b1\u200910.84 vs. 29.68\u2009\u00b1\u200914.32 mm\/h and 5.76\u2009\u00b1\u20091.57 vs. 11.44\u2009\u00b1\u20094.13 mg\/l, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.05). RA activity and antirheumatic drugs were stepped-down [12 (20.3%) and 35 (59.3%) patients showed good and moderate RA response, respectively]. The baseline viral load, absence of cirrhosis and SVR12 were the only predictors of disease control (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009\n                                 <jats:italic toggle=\"yes\">&lt;<\/jats:italic>\u20090.05). No drug-related adverse events or drug-related discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Unlike interferon, HCV elimination by DAAs significantly improves RA activity and treatment outcome with high safety and efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002015","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T20:03:15Z","timestamp":1606680195000},"page":"e239-e246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact"],"prefix":"10.1097","volume":"33","author":[{"given":"Sameh A.","family":"Lashen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hepatology and Gastroenterology Division"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa I.","family":"Metawea","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hepatology and Gastroenterology Division"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology and Immunology Division, University of Alexandria, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.1840360621","article-title":"Extrahepatic manifestations of hepatitis C among United States male veterans.","volume":"36","author":"El-Serag","year":"2002","journal-title":"Hepatology"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"e113579","DOI":"10.1371\/journal.pone.0113579","article-title":"Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in taiwan.","volume":"9","author":"Su","year":"2014","journal-title":"PLoS One"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"8916","DOI":"10.3748\/wjg.v19.i47.8916","article-title":"Immunological alterations in hepatitis C virus infection.","volume":"19","author":"Calvaruso","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate or leflunomide.","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R5-20240821","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.","volume":"18","author":"Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2014-206711","article-title":"A comparison of safety profiles of tumour necrosis factor \u03b1 inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejr.2017.07.002","article-title":"Impact of hepatitis C virus infection on disease activity, functional status, and ultrasonography findings in Egyptian rheumatoid arthritis patients.","volume":"40","author":"Gohar","year":"2018","journal-title":"Egyptian Rheumatol"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/acr.22463","article-title":"Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection.","volume":"67","author":"Patel","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3899\/jrheum.100092","article-title":"Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon-\u03b12a treatment for chronic hepatitis C infection.","volume":"37","author":"Yang","year":"2010","journal-title":"J Rheumatol"},{"key":"R10-20240821","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2169\/internalmedicine.50.4790","article-title":"Rheumatoid arthritis following a treatment with IFN-alpha\/ribavirin against HCV infection.","volume":"50","author":"Izumi","year":"2011","journal-title":"Intern Med"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5114\/ceh.2017.67782","article-title":"Recommendations for the treatment of hepatitis C in 2017.","volume":"3","author":"Halota","year":"2017","journal-title":"Clin Exp Hepatol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The disease activity score and the EULAR response criteria.","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2471\/BLT.19.231522","article-title":"Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis.","volume":"98","author":"Perazzo","year":"2020","journal-title":"Bull World Health Organ"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"4136253","DOI":"10.1155\/2018\/4136253","article-title":"Sofosbuvir based regimens in the treatment of chronic hepatitis c with compensated liver cirrhosis in community care setting.","volume":"2018","author":"Gayam","year":"2018","journal-title":"Int J Hepatol"},{"key":"R17-20240821","first-page":"1","article-title":"Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: a case-series.","volume":"5","author":"Kida","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14397595.2018.1558918","article-title":"Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis.","volume":"29","author":"Sebastiani","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R19-20240821","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2174\/1389450116666150825110532","article-title":"Innate and adaptive immune responses in chronic HCV infection.","volume":"18","author":"Dustin","year":"2017","journal-title":"Curr Drug Targets"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2017.49","article-title":"Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia.","volume":"112","author":"Emery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure.","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"R23-20240821","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3899\/jrheum.160983","article-title":"Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis C virus infection.","volume":"44","author":"Burton","year":"2017","journal-title":"J Rheumatol"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/TP.0000000000001606","article-title":"Immune reconstitution after HCV clearance with direct antiviral agents: potential consequences for patients with HCC?","volume":"101","author":"Werner","year":"2017","journal-title":"Transplantation"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:07:00Z","timestamp":1724364420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":24,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002015","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}